Frontline Therapy of B-cell Acute Lymphoblastic Leukemia: Harnessing Innovative Approaches to Improve Outcomes

Professor Martin Schrappe shares his insights on the frontline therapy of B-cell acute lymphoblastic leukemia at the 2025 EHA Annual Meeting.

Advances in Post-Covalent Bruton`s Tyrosine Kinase Inhibitor Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia

Professor Matthew Davids shares his insights on the advances in post-covalent Bruton`s tyrosine kinase inhibitor therapy for relapsed/refractory chronic lymphocytic leukemia at the 2025 EHA Annual Meeting.

AML Highlights from EHA 2025

Professor Petya Apostolova shares her insights on the Acute Myeloid Leukemia highlights from the 2025 EHA Annual Meeting.

Asciminib in the treatment of CML

Professor Dennis Kim shares his insights on the asciminib in the treatment of chronic myeloid leukemia after the 2025 EHA Annual Meeting.

POLARGO Trial Shows OS Benefit with Pola-R-GemOx in Transplant-Ineligible R/R DLBCL

Professor Matthew Matasar explains the highly anticipated results of the Phase III POLARGO trial after the 2025 EHA Annual Meeting.

Emerging Insights in the Secondary Acute Myeloid Leukemia in 2025

Professor Agnieszka Wierzbowska shares her thoughts on emerging insights in the secondary acute myeloid leukemia at the 2025 EHA Annual Meeting.

Highlights of Diffuse Large B-Cell Lymphoma at EHA 2025

Professor Thomas Oellerich shares his insights on the highlights of Diffuse Large B-Cell Lymphoma at the 2025 EHA Annual Meeting.

Management of Multiple Myeloma at EHA 2025

Professor Evangelos Terpos shares his insights on the management of Multiple Myeloma at the 2025 EHA Annual Meeting.

How to educate haematologists to better identify Gaucher disease?

Professor Sam Salek discusses how to educate haematologists to better identify Gaucher disease at the 2025 EHA Annual Meeting.

Diffuse large B cell lymphoma: Bispecifics in focus

Professor Martin Hutchings shares his insights on the role of bispecifics int the treatment of diffuse large B cell lymphoma at the 2025 EHA Annual Meeting.

Optimising the Management of FLT3mut+ R/R AML

Professor Mark Levis shares his insights on optimising the management of FLT3mut+ R/R AML at the 2025 EHA Annual Meeting.

Mapping the Evolving Chronic Lymphocytic Leukemia Treatment Landscape for the Optimal Patient Journey and Experience

Professor Dima El-Sharkawi shares her insights on the evolving chronic lymphocytic leukemia treatment landscape for the optimal patient journey and experience at the 2025 EHA Annual Meeting.

How to Improve the Awareness in Gaucher Disease?

Professor Pilar Giraldo shares her insights on how to improve the awareness in Gaucher disease at the 2025 EHA Annual Meeting.

Exploring the Landscape for FLT3-mutated Relapsed/Refractory Acute Myeloid Leukaemia

Professor Adolfo de la Fuente Burguera shares his insights on the landscape for FLT3-mutated relapsed/refractory acute myeloid leukaemia at the 2025 EHA Annual Meeting.

New therapeutic options and translational insights in ALL

Professor Cristina Papayannidis shares her insights on the new therapeutic options in acute lymphocytic leukemia at the 2025 EHA Annual Meeting.

Shaping the Treatment Landscape in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Professor Gail Roboz shares her insights on the treatment landscape in myelodysplastic syndromes and acute myeloid leukemia at the 2025 EHA Annual Meeting.